TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01235949

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix hexa
Description: Intramuscular injection, 3 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix hexa
Description: Intramuscular injection, 3 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix hexa
Description: Intramuscular injection, 3 doses
Study: NCT00629603

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: cytokine
Description: polymorphisms of fibrosis-relating cytokine were measured to validate the effectiveness of fibrosis in HCV-related chronic liver disease

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: cytokine polymorphisms
Description: Fibrosis-relating cytokine polymorphisms in hepatitis C virus-related chronic liver disease were measured to validate the degree of fibrosis

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: cytokine polymorphism
Description: fibrosis-relating cytokine polymorphism
Study: NCT04446052

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GM-CSF priming

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00925275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: I-131-CLR1404
Description: Single intravenous injection of 10 millicuries of I-131-CLR1404 given on Day 0
Study: NCT03840967

Intervention type: DRUG
Group type: OTHER
Intervention: Niraparib
Description: Niraparib will be administered as a flat-fixed daily dose depending on weight and platelet count. Subjects will take orally on a daily basis for 28 days. Each cycle = 28 days
Study: NCT04809337

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: After manuel therapy, the patients were allocated into two groups as Stabilization Exercise Group and Therapeutic Exercise Group randomly.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: After manuel therapy, the patients were allocated into two groups as Stabilization Exercise Group and Therapeutic Exercise Group randomly.
Study: NCT02400684

Intervention type: BIOLOGICAL
Intervention: blood samples
Description: Evolution of AMH before and after deep endometriosis surgery

Intervention type: BIOLOGICAL
Intervention: blood samples
Description: Evolution of AMH before and after deep endometriosis surgery
Study: NCT00836706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clarithromycin
Description: 500 mg Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIAXIN®
Description: 500 mg Tablet
Study: NCT04150718

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: slow-wave disruption
Description: A tone will be played through a speaker mounted over the bed that disrupts subjects while they are in slow-wave sleep. The tone will not be loud enough to wake up.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: slow-wave disruption
Description: A tone will be played through a speaker mounted over the bed that disrupts subjects while they are in slow-wave sleep. The tone will not be loud enough to wake up.
Study: NCT03058952

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction
Description: An 8-week standardized group program to teach mindfulness skills. In MBSR, participants meet for 2.5 hours per week for 8 weeks in a group format. Participants receive instruction in mindfulness meditation according to a standardized curriculum and have the opportunity to ask questions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Chronic Disease Self-Management Program
Description: The CDSMP is a structured program to teach self-management skills based on self-efficacy theory. CDSMP teaches self-management strategies and attempts to modify illness beliefs, enhance self-management capabilities and reinforce successful management strategies. CDSMP is based on self-efficacy theory, which posits that key determinants of behavior are: 1). self-efficacy (confidence in the ability to carry out an action) and 2). outcome expectancy (expectation that a particular goal will be achieved).
Study: NCT04539171

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain Neuroscience Education and Physical Exercise
Description: Patients assigned to the experimental group perform a PNE program consisting of seven sessions, with therapeutic PE. PNE is a health education intervention aims to provide up-to-date information on neuroscience advances in the field of chronic pain.
Study: NCT01168596

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rasagiline
Description: Comparison of Rasagiline versus placebo.~Rasagiline tablet, 1 mg, 1 per day, duration is approximately 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Comparison of Rasagiline versus placebo. Placebo tablet, 1 per day, duration is approximately 12 weeks.
Study: NCT01156844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: Indacaterol inhaled via Concept1, a single dose dry powder inhaler (SDDPI) for 16 days. Dosage and frequency varied according to randomization scheme.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: Indacaterol inhaled via Concept1, a single dose dry powder inhaler (SDDPI) for 16 days. Dosage and frequency varied according to randomization scheme.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: Indacaterol inhaled via Concept1, a single dose dry powder inhaler (SDDPI) for 16 days. Dosage and frequency varied according to randomization scheme.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Indacaterol
Description: Placebo inhaled via Concept1, a SDDPI. Frequency varied according to randomization scheme.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Indacaterol
Description: Placebo inhaled via Concept1, a SDDPI. Frequency varied according to randomization scheme.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Indacaterol
Description: Placebo inhaled via Concept1, a SDDPI. Frequency varied according to randomization scheme.
Study: NCT04746755

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthotic Insole: Lower Back
Description: This Insole is a full-length shaped orthotic insole, with a heel cup and an arch support. The insole can cover several shoe sizes and can be cut to the correct size to fit in the shoe.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthotic Insole: Heel
Description: This Insole is a horseshoe shaped flexible heel cup with a softer area where the heel would be expected.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthotic Insole: Knee to Heel
Description: This Insole is a ¾ length rigid orthotic insole with a softer area where the heel would be expected. Each insole will cover several shoe sizes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthotic Insole: Arch
Description: This Insole is a ¾ length shaped medical device with a softer area incorporated into the ball of foot and heel area and an external arch.~support and 6-8 mm metatarsal dome. The slim fit insole runs from the heel along under the arch of the foot and reaches to just behind the toes to prevent squashing the toes in tight fitting shoes.
Study: NCT04608708

Intervention type: OTHER
Intervention: The data of patients who had applied to the clinic for various reasons and were diagnosed with fibro-osseous lesions
Description: lesions diagnosed radiologically and followed up for at least one year were included in this study with the help of cone beam computed tomography.

Intervention type: OTHER
Intervention: The data of patients who had applied to the clinic for various reasons and were diagnosed with fibro-osseous lesions
Description: lesions diagnosed radiologically and followed up for at least one year were included in this study with the help of cone beam computed tomography.

Intervention type: OTHER
Intervention: The data of patients who had applied to the clinic for various reasons and were diagnosed with fibro-osseous lesions
Description: lesions diagnosed radiologically and followed up for at least one year were included in this study with the help of cone beam computed tomography.
Study: NCT03022721

Intervention type: OTHER
Intervention: No interventions are planned for this study.
Description: No interventions are planned for this study, it is purely observational.

Intervention type: OTHER
Intervention: No interventions are planned for this study.
Description: No interventions are planned for this study, it is purely observational.

Intervention type: OTHER
Intervention: No interventions are planned for this study.
Description: No interventions are planned for this study, it is purely observational.
Study: NCT00337168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clofarabine
Description: Induction: 40mg/m2/d; IV over 1 hr; days 1-5 Re-induction (if necessary): 40mg/m2/d; IV over 1 hr; days 1-5 Consolidation: 40mg/m2/d; IV over 1 hr; days 1-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Induction: 1g/m2/d; IV over 2 hrs; days 1-5 Re-induction (if necessary): 1g/m2/d; IV over 2 hrs; days 1-5 Consolidation: 1g/m2/d; IV over 2 hrs; days 1-4
Study: NCT00615888

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fast track patient management
Description: no bowel washout, patient controlled epidural anesthesia, early enteral feeding

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional management
Description: preoperative bowel washout, patient controlled analgesia, delayed start of enteral feeding
Study: NCT01235949

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix hexa
Description: Intramuscular injection, 3 doses

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix hexa
Description: Intramuscular injection, 3 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix hexa
Description: Intramuscular injection, 3 doses

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix-IPV/Hib
Description: Intramuscular injection, 1 dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix-IPV/Hib
Description: Intramuscular injection, 1 dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix-IPV/Hib
Description: Intramuscular injection, 1 dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix-IPV/Hib
Description: Intramuscular injection, 1 dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix-IPV/Hib
Description: Intramuscular injection, 1 dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix-IPV/Hib
Description: Intramuscular injection, 1 dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix-IPV/Hib
Description: Intramuscular injection, 1 dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix-IPV/Hib
Description: Intramuscular injection, 1 dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix-IPV/Hib
Description: Intramuscular injection, 1 dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix-IPV/Hib
Description: Intramuscular injection, 1 dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix-IPV/Hib
Description: Intramuscular injection, 1 dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix-IPV/Hib
Description: Intramuscular injection, 1 dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix-IPV/Hib
Description: Intramuscular injection, 1 dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix-IPV/Hib
Description: Intramuscular injection, 1 dose
Study: NCT04604106

Intervention type: DIAGNOSTIC_TEST
Intervention: Bayley Scale of Infant Development
Description: The Bayley Scale of Infant Development is a conventional instrument used to measure developmental outcome in infants.
Study: NCT03929588

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hand-held device supported by a mobile application
Description: Hand-held device supported by a mobile application to obtain refractive error of the eye.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hand-held device supported by a mobile application
Description: Hand-held device supported by a mobile application to obtain refractive error of the eye.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phoropter
Description: Manual refraction and ETDRS chart

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Autorefractor
Description: Automated refraction
Study: NCT04956822

Intervention type: OTHER
Intervention: Basic information
Description: Demographic data registration, medical history taking, physical examination. Electrocardiogram. Pulmonary function tests.

Intervention type: OTHER
Intervention: Basic information
Description: Demographic data registration, medical history taking, physical examination. Electrocardiogram. Pulmonary function tests.

Intervention type: OTHER
Intervention: Basic information
Description: Demographic data registration, medical history taking, physical examination. Electrocardiogram. Pulmonary function tests.

Intervention type: OTHER
Intervention: Basic information
Description: Demographic data registration, medical history taking, physical examination. Electrocardiogram. Pulmonary function tests.
Study: NCT02323048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methamphetamine
Description: : Twenty milligrams of MA (Desoxyn; Lundbeck Inc) tablets will be crushed and placed in 10 ml of Ora-Sweet syrup. Placebo drinks will consist of 10 ml of Ora-Sweet alone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methamphetamine
Description: : Twenty milligrams of MA (Desoxyn; Lundbeck Inc) tablets will be crushed and placed in 10 ml of Ora-Sweet syrup. Placebo drinks will consist of 10 ml of Ora-Sweet alone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methamphetamine
Description: : Twenty milligrams of MA (Desoxyn; Lundbeck Inc) tablets will be crushed and placed in 10 ml of Ora-Sweet syrup. Placebo drinks will consist of 10 ml of Ora-Sweet alone.
Study: NCT01235949

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix-IPV/Hib
Description: Intramuscular injection, 1 dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix-IPV/Hib
Description: Intramuscular injection, 1 dose
Study: NCT02323048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methamphetamine
Description: : Twenty milligrams of MA (Desoxyn; Lundbeck Inc) tablets will be crushed and placed in 10 ml of Ora-Sweet syrup. Placebo drinks will consist of 10 ml of Ora-Sweet alone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methamphetamine
Description: : Twenty milligrams of MA (Desoxyn; Lundbeck Inc) tablets will be crushed and placed in 10 ml of Ora-Sweet syrup. Placebo drinks will consist of 10 ml of Ora-Sweet alone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo (sugar pill)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo (sugar pill)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo (sugar pill)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo (sugar pill)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo (sugar pill)
Study: NCT00212004

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pioglitazone

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control
Study: NCT01999530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prazosin Hydrochloride
Description: Gradual upward titration to 15mg/day for approximately three weeks.
Study: NCT02014467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injection

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Elemental Calcium
Description: Oral, at least 600 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Elemental Calcium
Description: Oral, at least 600 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Oral, at least 400 IU

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D
Description: Oral, at least 400 IU
Study: NCT03524599

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention municipality
Description: In intervention municipalities, primary health care centres and the providers working within them will receive training and a range of community support mechanisms.
Study: NCT03321643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy
Study: NCT04956822

Intervention type: OTHER
Intervention: Functional scores
Description: depending on the diseases enrolled, ALS and KD chose ALS-FRS functional scores and CMT chose CMTNS2 functional scores

Intervention type: OTHER
Intervention: Functional scores
Description: depending on the diseases enrolled, ALS and KD chose ALS-FRS functional scores and CMT chose CMTNS2 functional scores
Study: NCT03321643

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or PET-CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV
Study: NCT02614833

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMP321 (eftilagimod alpha)
Description: In the placebo-controlled, double-blind randomisation stage, paclitaxel + IMP321 at the RPTD will be compared to paclitaxel + placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: In the placebo-controlled, double-blind randomisation stage, paclitaxel + placebo will be compared to paclitaxel + IMP321 at the RPTD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel will be given in both treatment arms (classified as Non IMP)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be given in both treatment arms (classified as Non IMP)
Study: NCT03321643

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV
Study: NCT01546519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: oral repeating dose of 150 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: oral repeating dose of 150 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: oral repeating dose of 150 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: oral repeating dose of 150 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: oral repeating dose of 150 mg once daily
Study: NCT03500367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rapamycin
Description: rapamycin, 2 mg a day, orally ,for 3months
Study: NCT03321643

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET-CT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study: NCT01871376

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal aflibercept injection 2.0mg
Description: Monthly 2.0mg intravitreal aflibercept injection, followed by Q8W dosing with 2.0mg intravitreal aflibercept injection or as often as monthly if needed for 1 year for both treatment naive and prior treatment arms.
Study: NCT01472926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenecteplase
Description: Intravenous (IV) tenecteplase 0.25 mg/kg (single bolus; maximum dose 25 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alteplase
Description: Intravenous alteplase 0.9mg/kg to maximum of 90mg, given as 10% bolus and 90% of dose over 1 hour infusion
Study: NCT05403619

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic test
Description: Cardiac Ultrasound in order to explore the causes of shortness of breath
Study: NCT03379155

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-based self-help program
Description: The intervention provided is based on the principles of cognitive behavioral therapy (CBT) (Bachem \& Maercker, 2013). The manual integrates a variety of approaches validated as treatments for PTSD, anxiety disorders, or depression; the selection focuses on exercises which are intended to target the main symptoms of AjD, namely preoccupations (e.g. constant rumination, excessive worry about the stressor) and failure to adapt (e.g. sleep disturbance, difficulties concentrating, loss of interest in previously enjoyable activities).
Study: NCT01235949

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix-IPV/Hib
Description: Intramuscular injection, 1 dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix-IPV/Hib
Description: Intramuscular injection, 1 dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Oral administration, 3 doses in the 24 hours following vaccination with an interval of 6-8 hours between doses and with dosage based on the subject's body weight
Study: NCT04509388

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Composition of Sports Drink
Description: The composition of sport drinks will be manipulated to determine the effect of drink composition on the appearance of ingested water in body fluid.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Composition of Sports Drink
Description: The composition of sport drinks will be manipulated to determine the effect of drink composition on the appearance of ingested water in body fluid.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Composition of Sports Drink
Description: The composition of sport drinks will be manipulated to determine the effect of drink composition on the appearance of ingested water in body fluid.
Study: NCT00954447

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, identical to Linagliptin tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Description: intended final marketed dose
Study: NCT03309202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05221304
Description: 25 mg dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05221304
Description: 25 mg dose